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Abstract The effects of butyrate on the modulation of urokinase 
plasminogen activator (uPA) and its receptor (uPAR) mRNAs 
were studied. While both mRNA levels were increased after stim- 
ulation by tumor necrosis factor alpha (TNFa), phorbol ester 
(PMA) and cycloheximide, they were inhibited by butyrate at 2.5 
to 25 mM. Nuclear run-on transcription assays indicated that 
uPA mRNA was modulated by butyrate at the transcriptional 
level but the uPAR gene was regulated at both transcriptional and 
post-transcriptional levels in the presence or absence of TNFa. 
In the presence of PMA, however, butyrate acts at the post- 
transcriptional level on both genes. 
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1. Introduction 
Butyrate is a short chain fatty acid produced in the lumen of 
the human colon by bacterial fermentation of dietary fibre [1]. 
At concentrations present in the lumen it inhibits cell prolifer- 
ation and stimulates cell differentiation [2]. Butyrate also in- 
duces apoptosis of colonic carcinoma cells in culture [2,3], in- 
creases c-jun and reduces c-myc expression i  colon cancer cells 
[4,5]. Butyrate responsive lements have been found in the 5' 
flanking regions of c-fos and mouse calbindin-D28k genes [1,6]. 
The effects of butyrate on the genes implicated in the cell 
surface proteases that may determine adenocarcinoma invasion 
and metastasis, however, are unknown. 
Proteolysis mediated by urokinase plasminogen activator 
(uPA) may be central to the processes of cell migration and 
invasiveness under normal and pathological conditions that 
include cancer invasion and metastasis [7]. uPA plays its cata- 
lytic role on the cell surface by binding specifically to its recep- 
tor (uPAR) with high affinity. Receptor-bound uPA activates 
the proenzyme plasminogen to form plasmin which initiates a 
proteolytic ascade that contributes to the degradation of base- 
ment membranes and the extracellular matrix [8]. The activity 
of uPA on the cell surface is regulated by the number of uPAR 
and the level of its inhibitors in the tumour cell microenviro- 
ment. In cancers, receptor-bound uPA activity is focussed at 
the invasive front [9]. High levels of uPA activity and uPAR 
gene expression in human cancers correlate with risk of recur- 
rence [10,11] and increasing evidence indicates that invasion 
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and metastasis by adenocarcinoma cells can be prevented by 
inhibiting uPA and uPAR production [12,13]. 
Tumor necrosis factor alpha (TNF~) is a pro-inflammatory 
cytokine that has cytocidal activity against a number of cancer 
cell lines and induces haemorrhagic necrosis of cancers in mice 
[14]. It stimulates a range ofmRNAs,  including uPA and uPAR 
mRNAs in human endothelial and colon cancer cells [15], but 
whether butyrate inhibits the increased uPA and uPAR expres- 
sion induced by TNF0~ or PMA is unclear. Similarly, whether 
butyrate regulates uPA and uPAR mRNA at the levels of 
transcription or post-transcription has received little attention. 
This paper reports that sodium butyrate inhibits uPA and 
uPAR mRNA expression in a dose-dependent manner in colon 
cancer cell lines regardless of whether they have been stimu- 
lated with TNFc~, PMA or cycloheximide. In the presence or 
absence of TNF~, butyrate acts, at least in part, at the tran- 
scriptional level on uPA gene expression, but acts at both the 
transcription and post-transcription levels on the expression of 
the uPAR gene. In the presence of PMA, however, butyrate 
acts at the post-transcriptional level on the expression of both 
genes. 
2. Materials and Methods 
2.1. Materials 
Recombinant human TNFa (activity: 1 unit ~0.0455 ng) was pro- 
vided by the Asahi Chemical Company, Tokyo, Japan. PMA and cyclo- 
heximide (CHX) were from Sigma Chem. Co., St. Louis, USA, and 
[~-32P]dCTP from Amersham Ltd., UK. 
2.2. Cell culture 
The HCT116 [16] (American Type Tissue Collection) and LIMI215 
cells [17] (Dr. R.T. Whitehead, Ludwig Institute for Cancer Research, 
Melbourne, Australia) were found to be free of Mycoplasma by 
Hoechst stain #33258 and of virus contamination bytransmission elec- 
tron microscopy of cell cultures throughout this study. Cells were main- 
tained in RPMI-1640 medium and washed with PBS and incubated 
overnight or for 4 h in RPMI serum-free media before stimulation. 
Immediately before harvest, cell viability was consistently found to be 
> 90%. 
2.3. cDNA probes 
The human uPA cDNA used was a 0.93 kb BgllI-BamHl fragment 
from the plasmid pcUKLTR6 provided by Dr. R. Miskin, the 
Weizmann Institute of Science, Israel [18]. The 1.144 kb human uPAR 
cDNA [19] used was a gift from Dr. E.K.O. Kruithof, Lausanne, Swit- 
zerland. Human 18 S ribosomal DNA (18 S rDNA) was provided by 
Dr. B.E.H. Maden, University of Liverpool, UK [20]. Human fl-actin 
cDNA [21] was a gift from Dr. H.D. Campbell, The Australian Na- 
tional University. Human ubiquitin cDNA [22] was a gift from Dr. R.T. 
Baker, The Australian National University. cDNA probes were la- 
belled with [~-3zp]dCTP by the random priming method [23]. 
2.4. RNA preparation and Northern blot analysis 
RNA was purified from cells using the guanidinium isothiocyanate 
method, electrophoresed on 1% formaldehyde-containing agarose gels, 
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transferred to a nitrocellulose membrane and further processed accord- 
ing to the method of Ausubel et al. [23]. The membranes were exposed 
to Kodak XAR film and multiple film exposure times were used to 
ensure linearity of band intensities. The intensities of mRNA bands in 
the autoradiographs were scanned and quantitated by a video den- 
sitometer (Model 620; Bio-Rad). mRNA intensities are calculated rela- 
tive to the intensity of the 18S rRNA internal control. The RNA 
molecular markers used were purchased from Promega corporation. 
2.5. Nuclear un-on transcription assay 
Nuclei were isolated from HCT116 cells treated with TNFc~, PMA 
or butyrate, according to the method previously described [24]. In brief. 
about 5 x 107 cells were washed twice with cold PBS and lysed in 4 ml 
NP-40 lysis buffer (10 mM Tris, pH 7.4110 mM NaCI/3 mM MgCIJ 
0.5% NP-40). Nuclei were then pelleted by centrifugation at600 x g for 
3 rain. For the transcription elongation reaction, freshly prepared nu- 
clei were incubated at 30°C for 30 min with [~-32p]UTP, and run-on 
analysis performed. In a given experiment, each filter was hybridized 
to DNA immobilized on nitrocellulose with the same amount of 
3:P-labelled RNA. The filters were then exposed at -70°C for 7-14 days 
using intensifying screens. The intensities of mRNA bands in the 
autoradiographs were scanned and quantitated by a video densitometer 
(Model 620; Bio-Rad). mRNA intensities are calculated relative to the 
intensity of the fl-actin internal control. 
3. Results and discussion 
3.1. Inhibition of uPA and uPAR mRNAs by sodium butyrate 
(NAB) 
To study whether expression of uPA and uPAR mRNAs  is 
inhibited by butyrate in the presence or absence of TNF~ (440 
units/ml), PMA (30 ng/ml) or CHX (20/.tg/ml) in colon cancer 
cells, RNA was isolated from cells treated with stimuli and 
analyzed by Northern-blotting. Unstimulated HCT116 cells ex- 
pressed low levels of 2.5 kb uPA and 1.4 kb uPAR transcripts 
but both mRNAs  were increased in the presence of TNFc~, 
PMA or CHX (Fig. 1 and 2). 
To investigate the role of butyrate in the regulation of uPA 
or uPAR mRNAs,  HCT l l6  cells were exposed to butyrate 
concentrations varying from 0.25-25 mM for 4 h. Northern 
blot analyses show inhibition of uPA and uPAR mRNAs at 
2.5 mM to 25 mM (Fig. 1A), in the range of concentrations 
found in the human colonic lumen. At 25 mM butyrate, uPA 
mRNA expression was completely inhibited and uPAR mRNA 
levels were reduced by 60% as determined by scanning den- 
sitometry. Similar butyrate ffects on uPA and uPAR mRNAs 
were found in another colon cancer cell lines, LIMI215 (data 
not shown). 
To determine the effects of butyrate on TNF~ or PMA- 
stimulated increases in uPA and uPAR mRNA levels, TNFct 
or PMA plus various concentrations ofbutyrate (0.25 25 mM) 
were added to the HCT116 cells for 4 h. Northern blot analyses 
showed a marked inhibition of uPA and uPAR mRNA expres- 
sion in cells. At 25 mM, butyrate inhibited about 90% of the 
uPA mRNA induced by TNFc~ or PMA, whereas uPAR 
mRNA was inhibited by about 50% in the same experiment, 
suggesting that uPA mRNA was more sensitive to butyrate 
than that of uPAR (Fig. 1B,C). 
In our experiments, butyrate had no effects on the total RNA 
yield or on cell viability. When the uPAR probe was eluted 
from the filters and the same RNA blot was then hybridized 
using 32p-labelled human fl-actin [21], ubiquitin cDNA [22] or 
18S rDNA,  no significant changes in the fl-actin and ubiquitin 
mRNAs (data not shown) or 18S rRNA were detected regard- 
less of whether the cells had been exposed to butyrate indicating 
that butyrate is selective in inhibiting gene expression. 
Butyrate is a naturally occurring short chain fatty acid that 
decreases cell growth, increases differentiation and induces ap- 
optosis in colon cancer cell lines [2], suggesting that locally 
produced butyrate may help protect colon epithelial cells from 
becoming neoplastic. Elevated uPA and uPAR expression has 
been reported for a number of human malignancies including 
colon, breast, bladder, and prostate cancer [10]. uPA-mediated 
proteolysis appears to be central to invasion by adeno- 
carcinoma cells and inhibition of uPA activity has become a 
target of anti-metastatic therapy [10]. The results presented in 
this paper show that, in colon cancer cells, there is a strong 
correlation between the degree of inhibition of uPA and uPAR 
gene expression and the concentration of sodium butyrate. Bu- 
tyrate produced by bacterial fermentation in the colon may 
therefore contribute to the prevention of uPA-mediated tumor 
cell invasion and metastasis. 
Furthermore, PMA induced increases of uPA and uPAR 
mRNAs that were markedly inhibited by sodium butyrate sug- 
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Fig. 1. Inhibition of uPA/uPAR mRNAs by sodium butyrate (NAB) in HCT116 cells. Cells were untreated or treated with PMA (30 ng/ml) or TNF~ 
(440 units/ml) for 4 h in the presence or absence of NaB. The same Northern blot was hybridized to uPA cDNA, uPAR cDNA and 18 S rDNA 
probes as indicated. (A) Dose-dependent i hibition of mRNAs accumulation by NaB. Autoradiographic exposure times were 5 days (for uPA and 
uPAR cDNA as probes) and 1.5 h (for 18 S rDNA as probe). Lane 1, untreated; lanes 24,  NaB at 0.25, 2.5 and 25 mM, respectively. (B) 
Dose-dependent i hibition of mRNAs accumulation by PMA plus NaB. Autoradiographic exposure times were 48 h (for uPA cDNA as probe), 24 
h (for uPAR cDNA as probe) and 1.5 h (for 18 S rDNA as probe). Lane 1, untreated; Lane 2, PMA; lanes 3-5, PMA plus NaB. NaB at 0.25, 2.5 
and 25 mM, respectively. (C) Dose-dependent i hibition of mRNAs accumulation by TNFc~ plus NaB. Autoradiographic exposure times were 48 
h (for uPA cDNA as probe), 72 h (for uPAR cDNA as probe) and 1 h (for 18 S rDNA as probe). Lane 1, untreated; Lane 2, TNF~; lanes 3-5, TNF~ 
plus NaB. NaB at 0.25, 2.5 and 25 mM, respectively. Each experiment was repeated at least three times and representative data shown in the figures. 
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gesting lumenal butyrate may also protect colon epithelial cells 
exposed to tumour promoters by down-regulating uPA system 
gene expression. TNF~ is produced by many cell types includ- 
ing activated monocytes, macrophages and lymphocytes [14]. 
Tumor-infiltrating macrophages, but not colon cancer cells, 
may also produce TNFc~ mRNA and protein in colon cancer 
tissue [25]. The inhibitory effect of butyrate on uPA and uPAR 
mRNAs stimulated by TNF~ suggests that the tumor microen- 
vironment may contribute to the regulation of uPA and uPAR 
gene expression in colonic cancers thereby influencing tumor 
invasiveness. Butyrate may also induce abnormal or trans- 
formed cell lines to convert o more normal phenotype and 
function [2]. These data combined with the inhibitory effects of 
butyrate on uPA and uPAR mRNAs expression reported here, 
may offer the prospect of developing new therapeutic ap- 
proaches to prevent invasion and metastasis by adenocarcino- 
mas of the colon. 
To investigate whether the inhibition of uPA or uPAR gene 
expression by butyrate depends on new protein synthesis, 
HCT116 cells were preincubated with CHX (20 ¢tg/ml) for 
30 min to ensure inhibition of protein synthesis at an early time 
point and then butyrate was added for 4 h. Northern blot 
analysis howed that in HCT116 cells, CHX alone induced uPA 
and uPAR mRNA expression suggesting that both genes are 
regulated by a labile repressor protein [15]. uPA and uPAR 
mRNAs were also induced by CHX in HCT116 cells stimulated 
by TNFc~ or PMA (Fig. 2), suggesting that stimulation of uPA 
and uPAR do not need de novo protein synthesis, uPA and 
uPAR mRNAs induced by CHX in the absence or presence of 
TNF~ or PMA were inhibited by sodium butyrate (Fig. 2) 
indicating that the effects of butyrate on uPA and uPAR gene 
expression do not require synthesis of new regulatory proteins 
in colon cancer cells. Similar effects of butyrate inhibition were 
found in LIM1215 cells (data not shown). No difference was 
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uPA. 
uPAR-  
18S rRNA-  
CHX + + + + - + + 
PMA + + + 
TNFa  + + + 
Butyrate  + + + 
Fig. 2. Inhibition of uPA/uPAR mRNAs by sodium butyrate (NAB) in 
the presence ofCHX in HCT116 cells. Cells were untreated or treated 
with CHX (20 /.tg/ml) for 4 h in the presence or absence of NaB 
(2.5 mM), PMA (30 ng/ml) and TNFc~ (440 units/ml). The same North- 
ern blot was hybridized to uPA cDNA, uPAR cDNA and 18S rDNA 
probes as indicated. Autoradiographic exposure times were 24 h (for 
uPA and uPAR as probes) and 4 h (for 18 S rDNA as probe). The 
symbol ' - '  and '+' indicate untreated and treated cells respectively. 
Each experiment was repeated at least hree times and representative 
data shown in the figures. 
A B 
control  NaB contro l  TNFa  TNFa+NaB 
uPAR.  
uPA-  
~-act in-  
pGEM-  
Fig. 3. Nuclear un-on transcription analysis of effects of sodium bu- 
tyrate (NAB) on uPA and uPAR gene transcription i HCT116 cells. 
Nuclei were isolated from HCT 116 cells treated with NaB (2.5 mM) (A) 
or TNFc~ (2,000 units/ml) plus NaB (2.5 mM) (B). Following in vitro 
transcription, RNA was purified from the nuclei and hybridized with 
uPAR cDNA, uPA cDNA, fl-actin cDNA or vector DNA (pGEM) 
immobilized on nitrocellulose filters. Hybridized 32P-labelled nuclear 
RNA was detected by autoradiography. Autoradiographic exposure 
time was 7 days for experiment (A), and 5 days for experiment (B). Each 
experiment was repeated at least wice and representative data shown 
in the figures. 
observed in the constitutively expressed 18 S ribosomal RNA 
(18 S rRNA), which served as a control. 
3.2. Effects of  butyrate on uPA and uPAR transcription in 
isolated nuclei 
To determine whether the effects of butyrate on the levels of 
uPA or uPAR mRNA act at the transcriptional level, nuclear 
run-on transcription assays were performed in HCT116 cells 
treated or untreated for 4 h with 2.5 mM butyrate in the pres- 
ence or absence of PMA and TNF~. As shown in Fig. 3, uPA 
and uPAR transcripts were expressed in nuclei from unstimu- 
lated HCT116 cells. While butyrate markedly inhibited uPA 
mRNA expression, it has no effect on uPAR mRNA indicating 
that the inhibitory effect of butyrate alone on uPA expression 
was mediated, at least in part, at the transcriptional level. By 
contrast, he inhibition of uPAR mRNA by butyrate alone was 
not mediated at the transcriptional level, but may act via post- 
transcriptional mechanisms including control points of mRNA 
processing, transport, translation or degradation, uPA and 
uPAR transcripts were increased in the cells exposed to TNFc~ 
(Fig. 3), but not PMA ([15] and data not shown). Both tran- 
scripts were also markedly reduced in the cells treated with 
butyrate plus TNFc~ (Fig. 3), but not butyrate plus PMA ([15] 
and data not shown). These assays indicate that the inhibitory 
effect of butyrate in the presence of TNF~ was mediated, at 
least in part, at the transcriptional level, whereas the inhibitory 
effect of butyrate in the presence of PMA may act via a post- 
transcriptional mechanism [15 and data not shown]. 
Previous reports showed that butyrate affects expression of 
genes including the c-fos and c-myc at both the transcription 
and post-transcription levels [1, 26]. Butyrate induces the c-Jbs 
proto-oncogene expression very rapidly at the post-trancrip- 
tional evel but up-regulated the c-fos gene at the transcriptional 
level at later time in a colon carcinoma cell line, Caco-2 [1]. 
c-myc gene expression, however, was down-regulated at the 
post-transcriptional level in the same cell line [26], indicating 
that complex mechanisms may be involved in the regulation of 
c-fos and c-myc gene expression by butyrate. In the case of the 
uPA system, butyrate modulated gene expression at both the 
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transcription (uPA) and post-transcription (uPAR) levels sug- 
gesting that different mechanisms may be involved in the regu- 
lation of uPA and uPAR gene expression. 
Human TNF~ regulates gene expression in eukaryotic ells 
by binding to the TNFc~ receptors [27]. In endothelial cells, 
TNF  receptor signal transduction pathways may involve 
cAMP, G-proteins, protein kinase C and other kinases [28]. The 
effects of TNF~ may be mediated through the transcriptional 
factor NF-xB which is activated by the sphingomyelin pathway 
in HL-60 cells [27]. The nuclear un-on experiment results re- 
ported here show that butyrate inhibits TNF~-induced uPAR 
mRNA at the transcriptional level suggesting that butyrate may 
affect uPAR gene expression by interacting with TNFc~ sig- 
nalling pathways. Therefore, the inhibitory effects of butyrate 
on TNF~- and PMA-induced changes in uPA and uPAR 
mRNA levels may reflect inhibition of TNFc~ signalling path- 
ways, inhibition of uPA gene transcription and degradation of 
both mRNAs at the level of post-transcription. 
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